» Articles » PMID: 19183764

Severe Macular Edema Induced by Pioglitazone in a Patient with Diabetic Retinopathy: a Case Study

Overview
Publisher Dove Medical Press
Date 2009 Feb 3
PMID 19183764
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

We report a case of severe diabetic macular edema (DME) that developed after pioglitazone was used by a patient with proliferative diabetic retinopathy. A 30-year-old woman with poorly controlled type 2 diabetes mellitus visited our clinic in 2004. She had moderate pre-proliferative diabetic retinopathy OU. Because of the rapid progression of the diabetic retinopathy, she received pan-retinal photocoagulation in both eyes. Two weeks before using pioglitazone, her visual acuity was 0.9 OD and 0.7 OS. On October 2007, pioglitazone was prescribed by her internist because of poorly controlled blood glucose level. Two weeks later, her body weight increased, and her face became edematous. Her visual acuity decreased to 0.5 OU, and ophthlamoscopy showed severe DME in both eyes. Two weeks after stopping pioglitazone, her visual acuity improved to 0.8 OD and 0.5 OS, but the DME was still severe in the optical coherence tomographic images. Then, one half the usual dose (25 mg) of spironolactone, a diuretic, was given and her macular edema was resolved. Her final visual acuity improved to 0.9 OD and 0.7 OS. We recommend that when a patient taking pioglitazone complains of decreased vision, the physician should promptly consult an ophthalmologist.

Citing Articles

Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients.

Susilawati E, Levita J, Susilawati Y, Sumiwi S Med Sci (Basel). 2023; 11(3).

PMID: 37606429 PMC: 10443323. DOI: 10.3390/medsci11030050.


Current Treatments for Diabetic Macular Edema.

Tatsumi T Int J Mol Sci. 2023; 24(11).

PMID: 37298544 PMC: 10253534. DOI: 10.3390/ijms24119591.


New anti-hyperglycaemic agents for type 2 diabetes and their effects on diabetic retinopathy.

Saw M, Wong V, Ho I, Liew G Eye (Lond). 2019; 33(12):1842-1851.

PMID: 31227789 PMC: 7002655. DOI: 10.1038/s41433-019-0494-z.


Optimizing Medical Management in Patients with Sight-Threatening Diabetic Retinopathy.

Mamtora S, Sandinha T, Carey P, Steel D Ophthalmol Ther. 2016; 6(1):105-114.

PMID: 27858333 PMC: 5449289. DOI: 10.1007/s40123-016-0069-z.


Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.

Kankanala S, Syed R, Gong Q, Ren B, Rao X, Zhong J Am J Transl Res. 2016; 8(5):2450-8.

PMID: 27347354 PMC: 4891459.


References
1.
Tokuyama T, Ikeda T, Sato K . Effects of haemodialysis on diabetic macular leakage. Br J Ophthalmol. 2000; 84(12):1397-400. PMC: 1723329. DOI: 10.1136/bjo.84.12.1397. View

2.
Colucciello M . Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol. 2005; 123(9):1273-5. DOI: 10.1001/archopht.123.9.1273. View

3.
Herz M, Johns D, Reviriego J, Grossman L, Godin C, Duran S . A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther. 2003; 25(4):1074-95. DOI: 10.1016/s0149-2918(03)80068-1. View

4.
Ryan Jr E, Han D, Ramsay R, Cantrill H, Bennett S, Dev S . Diabetic macular edema associated with glitazone use. Retina. 2006; 26(5):562-70. DOI: 10.1097/00006982-200605000-00011. View

5.
ARONOFF S, Rosenblatt S, Braithwaite S, EGAN J, Mathisen A, Schneider R . Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000; 23(11):1605-11. DOI: 10.2337/diacare.23.11.1605. View